T-type Ca 2+ channels are present in cardiovascular, neuronal, and endocrine systems; and they are now receiving attention as novel therapeutic targets. Many drugs and compounds non-specificaly block T-type Ca 2+ channels. Certain dihydropyridine compounds, such as efonidipine, have blocking activity on both L-type and T-type Ca 2+ channels which possibly underlies their excellent clinical profiles such as minimum reflex tachycardia and renal protection. Selective inhibitors of T-type Ca 2+ channels, such as non-hydrolyzable mibefradil and R(−)-efonidipine, are powerful pharmacological tools for further studies and may lead to the development of novel therapeutic strategies.
T-type Ca 2+ channels
The T-type Ca 2+ channel has properties different from those of the L-type such as more negative voltage range of activation and inactivation, rapid gating kinetics, and resistance to standard Ca 2+ blockers ( Table 1) . Three different cDNAs for T-type Ca 2+ channels have been cloned, and information on their distribution and function is now accumulating (1) . T-type Ca 2+ channels are expressed throughout the body, including nervous tissue, heart, kidney, smooth muscle, and many endocrine organs. T-type Ca 2+ channels in the brain are considered to be involved in repetitive low threshold firing (2) and nociception (3) . In the heart, T-type Ca 2+ channels are expressed in the sinoatrial node and are considered to participate in cardiac pacemaking (4, 5) , but not in normal myocardial contraction, as described below. The expression of T-type Ca 2+ channels was shown to be increased in immature hearts (6) and proposed to be involved in the development of pathological conditions such as ventricular hypertrophy (6 -8) , myocardial infarction (9) , cardiomyopathy (10, 11) , heart failure (12) , and atrial fibrilation (13, 14) . T-type Ca 2+ channels are expressed in various arteries and veins with a distribution different from that of L-type Ca 2+ channels and are considered to participate in regulation of microcirculation (15 -18) . T-type Ca 2+ channels are also expressed in the smooth muscle of bronchi, illeum, colon, bladder, and uterus. Involvement of T-type Ca 2+ channels in the secretion of various hormones has been postulated including aldosterone (19) , renin (20) , atrial natriuretic peptide (21) , and insulin (22) . Thus, T-type Ca 2+ channels are now anticipated to be novel therapeutic targets for the treatment of various cardiovascular disorders such as heart failure, arrhythmia, and hypertension and neuronal disorders such as epilepsy and pain. Inhibition of T-type Ca 2+ channels may result in long-term organ protection through improvement of local microcirculation and reduction of adverse hormonal effects.
Diversity of drugs with T-type Ca 2+ channel blocking activity
Ca 2+ channel blockers, which block L-type Ca 2+ channels, are classified into three major groups, phenylalkylamines (verapamil, etc.), benzotiazepines (diltiazem, etc.), and dihydropyridines (nifedipine, etc.). These drugs in general do not inhibit T-type Ca 2+ channels at therapeutic concentrations, except for certain dihydropyridine compounds that have dual blocking action on the L-type and T-type Ca 2+ channels. Ca 2+ blockers with low specificity such as flunarizine and cinnarizine are reported to have T-type Ca 2+ channel-blocking activity, but its relation to their therapeutic potential is uncertain (23) .
Mibefradil (Ro 40-6967) ( Fig. 1 ) is a tetralol derivative that blocks T-type Ca 2+ channels at concentrations lower than that to block L-type Ca 2+ channels. It appeared to be a promising drug for the treatment of hypertension and angina pectoris (24) . It reduced blood pressure and heart rate without supressing myocardial contraction. Mibefradil also had beneficial effects in various animal models of heart failure and improved survival rate in a rat chronic myocardial infarction model (25) ; this was possibly accompanied by antiarrhythmic effects through T-type Ca 2+ channel blockade. Unfortunately, however, the drug had to be withdrawn from the market due to drug interaction at the cytochrome P-450 3A4 enzyme which was unrelated to T-type Ca 2+ channel blockade. Some of the pharmacological profiles of mibefradil appear to be shared by dihydropyridine Ca 2+ blockers with blocking action on both L-type and T-type Ca 2+ channels as described below. It was recently reported that the L-type Ca 2+ channel blocking activity of mibefradil was due to production of an active metabolite by intracellular hydrolysis, and that a non-hydrolyzable analogue of mibefradil selectively inhibits the T-type Ca 2+ channel (26) .
There are many other compounds that have been reported to inhibit the T-type Ca 2+ channel, but most of them also affects other ion channels and transporters, and no specific inhibitor of the channel has been established at present (23) . These include antiepileptic drugs phenytoin and ethosuximide, anesthetics isoflurane and pentobarbital, and drugs acting on the central nervous system such as haloperidol and pimozide. As T-type Ca 2+ channels are reported to be involved in neuron excitation and hormone secretion, it is possible that the T-type Ca 2+ channel-blocking effect of these drugs contribute to their therapeutic potential. Kurtoxin, a peptide isolated from a venomous scorpion, was reported to inhibit T-type Ca 2+ channels, but the toxin was found to block other types of Ca 2+ channels as well (27) . 
Efonidipine, a dihydropyridine with dual blocking activity on L-type and T-type Ca 2+ channels
Efonidipine hydrochloride (efonidipine) ( Fig. 1 ) (28), an anti-hypertensive and anti-anginal drug with dihydropyridine structure, was found to block both L-type and T-type Ca 2+ channels (29, 30) , and its excellent clinical profiles have received attention. The basic concept of efonidipine action, dual blocking of L-type and T-type Ca 2+ channels, originated from its characteristic effect on the cardiac pacemaker. Efonidipine was developed as a drug with slow onset and long duration of action similarly to many other new generation dihydropyridine Ca 2+ antagonists (28) . While the hypotensive effect of standard dihydropyridine Ca 2+ antagonists are accompanied with reflex tachycardia, that of efonidipine was shown to be accompanied by no or less reflex tachycardia in conscious rabbits (31) , anesthetized dogs (32), and human (33, 34) , or rather decreases in heart rate in open chest dogs (35 -37) . This was initially considered to be the result of efonidipine's slow onset of action. However, as efonidipine had potent negative chronotropic effects on isolated right atria (38, 39) , we speculated that the drug might have direct effects on the sino-atrial node. Thus, we performed standard glass microelectrode recordings of spontaneous action potentials in isolated sino-atrial node tissue from the rabbit (29) and guinea pig (30) , and we found that efonidipine prominently prolongs the late phase 4 depolarization (pacemaker depolarization) ( Fig. 2 ). Such effect was not observed with many other dihydropyridine and non-dihydropyridine Ca 2+ antagonists. The change in action potential waveform produced by efonidipine was very similar to that by 40 µM nickel, which specifically inhibits T-type Ca 2+ channels in myocardial cells (4, 29) . Similar change in action potential waveform was observed after application of mibefradil (40) and after application of efonidipine to isolated sino-atrial node cells (41) . Computer simulation of the effect of T-type Ca 2+ channel blockade on sino-atrial node action potential based on data for individual membrane currents predicted a characteristic waveform smilar to what was actually observed after Ni 2+ or efonidipine application in our experiments (42) . Voltage clamp exeriments with isolated guinea-pig ventricular cardiomyocytes showed that efonidipine inhibits both L-type and T-type Ca 2+ channels concentration-dependently (30) . The recombinant human T-type Ca 2+ channel (α 1H ) current was inhibited by mibefradil (IC 50 = 0.89 µM) and efonidipine (IC 50 = 0.43 µM, ref. 43). These results indicated that efonidipine produces characteristic prolongation of late phase 4 depolarization of the sino-atrial node action potential through inhibition of both L-type and T-type Ca 2+ channels, leading to its potent negative chronotropic effect. Thus, although the varying contribution of T-type Ca 2+ channels to cardiac pacemaking among experimental animal species and under different pathophysiological conditions of the heart must be carefully taken into account (5), addition of T-type Ca 2+ channel-inhibitory activity to Ca 2+ blockers appears to increase their bradycardiac potency.
The major disadvantage of standard dihydropyridine antihypertensive drugs is their tendency to produce reflex tachycardia. Elevated sympathetic cardioacceleratory drive results in increased heart rate and increased myocardial oxygen demand, and this may lead to aggravation of myocardial ischemia. Efonidipine, which has bradycardiac activity based on dual inhibition of L-type and T-type Ca 2+ channels, is expected to reduce heart rate or attenuate the increase in heart rate accompanying hypotension. This was indeed the case with experimental animals as mentioned above and also in human patients with hypertension (44) . This may partly be explained by the mode of action of efonidipine on the T-type Ca 2+ channel; in voltage-clamped ventricular myocytes, inhibition of the T-type Ca 2+ channel current by efonidipine was more prominent when the current was activated at higher frequency (45) . The bradycardiac nature of efonidipine effects leads us to the anticipation that application of the drug would improve myocardial oxygen demand and protect the myocardium against ischemic insult. In fact, in dogs, efonidipine decreased heart rate and myocardial oxygen demand, increased cardiac output (37) , coronary blood flow, myocardial oxygen tension (pO 2 ) (35, 36), and ATP level (32) . In patients with angina pectoris, efonidipine attenuated the increase in heart rate during treadmil excercise and was superior to nifedipine in improving the overall exercise tolerance (33) .
The T-type Ca 2+ channel is present most abundantly in the sino-atrial node, but is also present in the ventricle and atrium; the density is higher in the atrium than in the ventricle (21, 46) . Confocal fluorescense microscopy has revealed a difference in triggering mechanisms of Ca 2+ release from the sarcoplasmic reticulum (SR) between the ventricle and atria: simultaneous activation by Ca 2+ influx from T-tubules versus sequential activation by Ca 2+ waves originating from subsarcolemmal regions, respectively (47) . Contractile force and Ca 2+ transient measurements with Ni 2+ and mibefradil showed that in both atria and ventricle, the T-type Ca 2+ channels is not the pathway for Ca 2+ influx to trigger SR Ca 2+ release under normal conditions (46, 48) (Fig. 3) . Involvement of L-type but not T-type Ca 2+ channels in myocardial contraction suggests that the T-type Ca 2+ channel blocking activity of Ca 2+ antagonists would increase their negative chronotropic potency without increasing their negative inotropic potency. This was indeed the case with efonidipine in isolated myocardial preparations. In case of nifedipine and verapamil, the potencies of the chronotropy and inotropy expressed in terms of EC 30 values were about the same, while in the case of efonidipine, the potency of inotropy was 1 / 300 of the potency of chronotropy (38, 39) .
T-type Ca 2+ channels are considered to contribute to the regulation of blood flow and to be differentially distributed from L-type Ca 2+ channels. In renal microcirculation, L-type Ca 2+ channels are distributed mainly in the afferent arteriole, while T-type Ca 2+ channels appear to be present in both afferent and efferent arterioles (Fig. 4) . Drugs affecting L-type Ca 2+ channels such as nifedipine dilates the afferent arteriole, while mibefradil and efonidipine, which blocks both L-type and T-type Ca 2+ channels, dilate both afferent and efferent arterioles in various animal species (16 -18, 49 -51) . Furthermore, efonidipine increased glomelular filtration rate without increasing intraglomelular pressure and resulted in renal protection in rats (52) . Renal protection by efonidipine was also observed in hypertensive patients complicated by renal disorders, and the degree was comparable to that by angiotensin converting enzyme inhibitors (17) . 
Possible chemical structure underlying T-type Ca 2+ channel blocking activity of dihydropyridines
When compared with nicardipine, efonidipine has a bulky side chain on both C3 and C5 position of the dihydropyridine ring (Fig. 1) . The C5 position of efonidipine is a phosphonate moiety, which is different from the carboxymethylester side chain present in most other dihydropyridine Ca 2+ blockers. We examined the pharmacological properties of various dihydropyridine compounds including nicardipine, nicardipine with a phosphonate moiety at C5 position, nicardipine with an efonidipine type side chain at C3 position, and efonidipine. The results showed that the phosphonate moiety at the C5 position is important for the characteristic pharmacological profiles of efonidipine, that is, inhibition of T-type Ca 2+ channels, marked prolongation of the late plateau of sino-atrial node action potential, and high negative chronotropic potency (53, 54) .
Among the dihydropyridine compounds we examined, cilnidipine had pharmacological profiles similar to efonidipine. Cilnidipine was developed as a slow and long acting antihypertensive drug (55) . The hypotensive action of cilnidipine is accompanied by no or minimum reflex tachycardia in experimental animals and in patients with hypertension. In addition to its blocking effect on L-type Ca 2+ channels, cilnidipine blocks Ntype Ca 2+ channels present on sympathetic nerve endings; this was considered to underlie the abovementioned pharmacological profile of the drug. We examined the effects of cilnidipine on isolated myocardial preparations and observed prolongation of the late pacemaker depolarization of sino-atrial node action potential and inhibition of T-type Ca 2+ channels (56) . Although details await fruther investigation, it is possible that the T-type Ca 2+ channel-blocking activity of cilnidipine contributes to its its pharmacological profiles. Interestingly, the C5 side chain of cilnidipine is more bulky than the carboxymethylester present in most other dihydropyridine Ca 2+ blockers. Thus, it is possible that a phosphonate or related bulky side chain at the C5 position of the dihydropyridine ring is the chemical structure underlying the T-type Ca 2+ channel blocking activity. Another evidence in support for this hypothesis is that CD832, a dihydropyridine compound which also has a bulky side chain at the C5 position, inhibits both L-type and T-type Ca 2+ channels (57) . However, the C5 side chain of aranidipine, which also blocks T-type Ca 2+ channels (58), is not bulky. Thus, the structure-activity relationship for the T-type Ca 2+ channel blocking action of dihydropyridine compounds may not be simple.
Dihydropyridine compounds in clinical use, except nifedipine, has a chiral carbon at position C4 of the dihydropyridine ring, whose configuration may affect the pharmacological property of the compound. The pharmacological activity of dihydropyridine compounds are generally considered to be stereo-selective; one enantiomer is 3-to 1000-fold more potent than the other when determined by parameters reflecting L-type Ca 2+ channel-blocking activity (59) . In contrast, T-type Ca 2+ channel-blockade by dihydropyridine compounds may not be stereoselective. It was recently shown with recombinant T-type Ca 2+ channels (60) and in isolated cardiomyocytes (61) that the R(−) enantiomer of efonidipine (R(−)-efonidipine) selectively inhibits Ttype Ca 2+ channels. In cardiomyocytes, 1 µM R(−)efonidipine inhibited T-type Ca 2+ current by more than 80%, while it had no significant effect on L-type Ca 2+ current and intracellular Ca 2+ transient (61) . Thus, R(−)efonidipine appears to be a powerful pharmacological tool for further studies on the physiological and pathophysiological roles of the T-type Ca 2+ channel.
Conclusion
Certain drugs and compounds including mibefradil and efonidipine have blocking activity on both L-type and T-type Ca 2+ channels. Addition of T-type Ca 2+ channel-blocking activity to dihydropyridine Ca 2+ blockers possibly results in improved clinical profiles such as minimum reflex tachycardia and renal protection ( Table 2 ). Selective inhibitors of T-type Ca 2+ channels, 
